Reuters logo
Vical licenses technology, vaccine booster to Bristol-Myers; shares up
September 13, 2012 / 8:17 PM / 5 years ago

Vical licenses technology, vaccine booster to Bristol-Myers; shares up

(Reuters) - Vical Inc (VICL.O) licensed its DNA immunization technology platform and its vaccine adjuvant to Bristol-Myers Squibb Co (BMY.N), sending its shares up as much as 14 percent before the bell.

Under the non-exclusive, global license, Bristol-Myers will use Vical’s technology to discover antibodies.

    Vical will also supply its product Vaxfectin, an adjuvant which has been proven to improve immune response to vaccines, to Bristol-Myers from time to time.

    Financial terms of the deal were not disclosed. San Diego-based Vical had cash and investments of about $97 million as of June 30, 2012.

    The company’s shares, which have lost about 15 percent of their value this year, were up 14 percent at $4.30 in trading before the bell on Thursday.

    Reporting by Vidya P L Nathan; Editing by Sreejiraj Eluvangal

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below